Fc-fusion proteins in therapy: An updated view

Current Medicinal Chemistry

Volumn 24, Issue 12, 2017, Pages 1228-1237

  Jafari, Reza ^a   Zolbanin, Naime M ^b   Rafatpanah, Houshang ^a   Majidi, Jafar ^b,c   Kazemi, Tohid ^b,c  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antibody; Fc region; Fc fusion proteins; FcRn; Immunotherapy

Indexed keywords

ALT 803; AMINO ACID; ASUNERCEPT; BLISIBIMOD; CNTO 528; CNTO 530; DULAGLUTIDE; ETANERCEPT; FC FUSION PROTEIN; FC RECEPTOR; HYBRID PROTEIN; TREBANANIB; UNCLASSIFIED DRUG; FC RECEPTOR, NEONATAL; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN FC FRAGMENT;

DRUG APPROVAL; DRUG MECHANISM; HUMAN; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMAL; CHEMISTRY; IMMUNOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; RECEPTORS, FC;

EID: 85025072920     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666170113112759     Document Type: Review

References (89)

1. Beck, A.; Reichert, J.M. Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs, 2011, 3(5), 415-416.
2. Huang, C. Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr. Opin. Biotechnol., 2009, 20(6), 692-699.
3. Chamow, S.M.; Ryll, T.; Lowman, H.B.; Farson, D. Therapeutic Fc-fusion proteins; John Wiley & Sons, Germany, 2013.
4. Suzuki, T.; Ishii-Watabe, A.; Tada, M.; Kobayashi, T.; Ka-nayasu-Toyoda, T.; Kawanishi, T.; Yamaguchi, T. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J. Immunol., 2010, 184(4), 1968-1976.
5. Ghose, S.; Hubbard, B.; Cramer, S.M. Binding capacity differences for antibodies and Fc-fusion proteins on protein A chromatographic materials. Biotechnol. Bioeng., 2007, 96(4), 768-779.
6. Shimamoto, G.; Gegg, C.; Boone, T.; Quéva, C. Peptibod-ies: A flexible alternative format to antibodies. MAbs, 2012, 4(5), 586-591.
7. Archdeacon, P.; Dixon, C.; Belen, O.; Albrecht, R.; Meyer, J. Summary of the US FDA approval of belatacept. Am. J. Transplant., 2012, 12(3), 554-562.
8. Genovese, M.C.; Becker, J-C.; Schiff, M.; Luggen, M.; Sherrer, Y.; Kremer, J.; Birbara, C.; Box, J.; Natarajan, K.; Nuamah, I.; Li, T.; Aranda, R.; Hagerty, D.T.; Dougados, M. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N. Engl. J. Med., 2005, 353(11), 1114-1123.
9. Vincenti, F.; Larsen, C.; Durrbach, A.; Wekerle, T.; Nashan, B.; Blancho, G.; Lang, P.; Grinyo, J.; Halloran, P.F.; Solez, K.; Hagerty, D.; Levy, E.; Zhou, W.; Natarajan, K.; Charpentier, B. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med., 2005, 353(8), 770-781.
10. Liu, E.H.; Siegel, R.M.; Harlan, D.M.; OShea, J.J. T cell-directed therapies: lessons learned and future prospects. Nat. Immunol., 2007, 8(1), 25-30.
11. Schmidt, S.R. Fusion-proteins as biopharmaceuticals: applications and challenges. Curr. Opin. Drug Discov. Devel., 2009, 12(2), 284-295.
12. Gatto, B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr. Opin. Investig. Drugs, 2008, 9(11), 1216-1227.
13. Capon, D.J.; Chamow, S.M.; Mordenti, J.; Marsters, S.A.; Gregory, T.; Mitsuya, H.; Byrn, R.A.; Lucas, C.; Wurm, F.M.; Groopman, J.E. Designing CD4 immunoadhesins for AIDS therapy. Nature, 1989, 337(6207), 525-531.
14. Capon, D.J.; Ward, R.H. The CD4-gp120 interaction and AIDS pathogenesis. Annu. Rev. Immunol., 1991, 9(1), 649-678.
15. Lasky, L.A.; Nakamura, G.; Smith, D.H.; Fennie, C.; Shi-masaki, C.; Patzer, E.; Berman, P.; Gregory, T.; Capon, D.J. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell, 1987, 50(6), 975-985.
16. Smith, D.H.; Byrn, R.A.; Marsters, S.A.; Gregory, T.; Groopman, J.E.; Capon, D.J. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. Science, 1987, 238(4834), 1704-1707.
17. Czajkowsky, D.M.; Hu, J.; Shao, Z.; Pleass, R.J. Fc-fusion proteins: New developments and future perspectives. EMBO Mol. Med., 2012, 4(10), 1015-1028.
18. Scheinberg, M.A.; Kay, J. The advent of biosimilar therapies in rheumatologyO brave new world. Nat. Rev. Rheumatol., 2012, 8(7), 430-436.
19. Moreland, L.W.; Schiff, M.H.; Baumgartner, S.W.; Tindall, E.A.; Fleischmann, R.M.; Bulpitt, K.J.; Weaver, A.L.; Keystone, E.C.; Furst, D.E.; Mease, P.J.; Ruderman, E.M.; Horwitz, D.A.; Arkfeld, D.G.; Garrison, L.; Burge, D.J.; Blosch, C.M.; Lange, M.L.; McDonnell, N.D.; Weinblatt, M.E. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med., 1999, 130(6), 478-486.
20. Weinblatt, M.E.; Kremer, J.M.; Bankhurst, A.D.; Bulpitt, K.J.; Fleischmann, R.M.; Fox, R.I.; Jackson, C.G.; Lange, M.; Burge, D.J. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med., 1999, 340(4), 253-259.
21. Strohl, W.R. Fusion proteins for half-life extension of biologics as a strategy to make biobetters. BioDrugs, 2015, 29(4), 215-239.
22. Weinberg, J.M.; Lebwohl, M. Advances in Psoriasis; Springer, USA, 2014.
23. Howell, M.D.; Parker, M.L.; Mustelin, T.; Ranade, K. Past, present, and future for biologic intervention in atopic dermatitis. Allergy, 2015, 70(8), 887-896.
24. Holash, J.; Maisonpierre, P.C.; Compton, D.; Boland, P.; Alexander, C.R.; Zagzag, D.; Yancopoulos, G.D.; Wiegand, S.J. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science, 1999, 284(5422), 1994-1998.
25. Augustin, H.G.; Koh, G.Y.; Thurston, G.; Alitalo, K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat. Rev. Mol. Cell Biol., 2009, 10(3), 165-177.
26. Bach, F.; Uddin, F.J.; Burke, D. Angiopoietins in malignancy. Eur. J. Surg. Oncol., 2007, 33(1), 7-15.
27. Adams, R.H.; Alitalo, K. Molecular regulation of angio-genesis and lymphangiogenesis. Nat. Rev. Mol. Cell Biol., 2007, 8(6), 464-478.
28. Alitalo, K.; Tammela, T.; Petrova, T.V. Lymphangiogenesis in development and human disease. Nature, 2005, 438(7070), 946-953.
29. Herbst, R.S.; Hong, D.; Chap, L.; Kurzrock, R.; Jackson, E.; Silverman, J.M.; Rasmussen, E.; Sun, Y.N.; Zhong, D.; Hwang, Y.C.; Evelhoch, J.L.; Oliner, J.D.; Le, N.; Rosen, L.S. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J. Clin. Oncol., 2009, 27(21), 3557-3565.
30. Karlan, B.Y.; Oza, A.M.; Richardson, G.E.; Provencher, D.M.; Hansen, V.L.; Buck, M. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J. Clin. Oncol., 2012, 30(4), 362-371.
31. Monk, B.J.; Poveda, A.; Vergote, I.; Raspagliesi, F.; Fujiwara, K.; Bae, D-S.; Oaknin, A.; Ray-Coquard, I.; Provencher, D.M.; Karlan, B.Y.; Lhommé, C.; Richardson, G.; Rincón, D.G.; Coleman, R.L.; Herzog, T.J.; Marth, C.; Brize, A.; Fabbro, M.; Redondo, A.; Bamias, A.; Tassoudji, M.; Navale, L.; Warner, D.J.; Oza, A.M. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRI-NOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol., 2014, 15(8), 799-808.
32. Coleman, R.L.; Monk, B.J.; Sood, A.K.; Herzog, T.J. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat. Rev. Clin. Oncol., 2013, 10(4), 211-224.
33. Gerald, D.; Chintharlapalli, S.; Augustin, H.G.; Benjamin, L.E. Angiopoietin-2: An attractive target for improved antiangiogenic tumor therapy. Cancer Res., 2013, 73(6), 1649-1657.
34. Hall, M.; Gourley, C.; McNeish, I.; Ledermann, J.; Gore, M.; Jayson, G.; Perren, T.; Rustin, G.; Kaye, S. Targeted anti-vascular therapies for ovarian cancer: Current evidence. Br. J. Cancer, 2013, 108(2), 250-258.
35. Scheinberg, M.A.; Srinivasan, D.; Martin, R.S. The potential role of blisibimod for the treatment of systemic lupus erythematosus. Int. J. Clin. Rheumatol., 2014, 9(2), 121-134.
36. Bossen, C.; Schneider, P., Eds.; BAFF, APRIL and their receptors: structure, function and signaling. Sem. Immunol., 2006, 18(5), 263-275.
37. Laâbi, Y.; Strasser, A. Immunology. Lymphocyte survival-ignorance is BLys. Science, 2000, 289(5481), 883-884.
38. Mackay, F.; Browning, J.L. BAFF: a fundamental survival factor for B cells. Nat. Rev. Immunol., 2002, 2(7), 465-475.
39. Schneider, P. The role of APRIL and BAFF in lymphocyte activation. Curr. Opin. Immunol., 2005, 17(3), 282-289.
40. Mackay, F.; Mackay, C.R. The role of BAFF in B-cell maturation, T-cell activation and autoimmunity. Trends Immunol., 2002, 23(3), 113-115.
41. Mackay, F.; Woodcock, S.A.; Lawton, P.; Ambrose, C.; Baetscher, M.; Schneider, P.; Tschopp, J.; Browning, J.L. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J. Exp. Med., 1999, 190(11), 1697-1710.
42. Yusof, M.; Vital, E.M.; Emery, P. Biologics in systemic lupus erythematosus: current options and future perspectives. Br. J. Hosp. Med. (Lond.), 2014, 75(8), 440-447.
43. Davidson, A. BAFF and APRIL and Their Receptors. Encyclopedia of Medical Immunology; Springer, USA: 2014, pp. 181-187.
44. Stohl, W. Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr. Rheumatol. Rep., 2012, 14(4), 303-309.
45. Furie, R.; Scheinberg, M.; Leon, G. Effects of blisibimod, a subcutaneous inhibitor of BAFF, in patients with SLE. Ann. Rheum. Dis., 2013, 72(Suppl. 3), 90. [abstract OP116].
46. Richard, A.F.; Morton, A.S.; Gustavo, L.; Edgar, B.R.; Matthew, T.; Renee, S.M.; Michelle, P. Blisibimod, an Inhibitor of B Cell Activating Factor, in Patients with Moderate-to-Severe Systemic Lupus Erythematosus. In: 2012 ACR/ARHP Annual Meeting, 9-14 November, Wiley-Blackwell: Washington, DC, 2012.
47. Richard, A.F.; Matthew, T.; Alvina, C.; Renee, S.M.; Colin, H.; Morton A.S. Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Serum Immunoglobulins and Infection Risk in Patients with Systemic Lupus Erythematosus: Observations from the Placebo-Controlled Pearl-SC and Open-Label Extension Studies. In: 2013 ACR/ARHP Annual Meeting, 25-30 October, Wiley-Blackwell: San Diego, CA, 2013.
48. Furie, R.A.; Leon, G.; Thomas, M.; Petri, M.A.; Chu, A.D.; Hislop, C.; Martin, R.S.; Scheinberg, M.A.; PEARL-SC Study. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann. Rheum. Dis., 2015, 74(9), 1667-1675.
49. Jordan, N.; Lutalo, P.M.; DCruz, D.P. Novel therapeutic agents in clinical development for systemic lupus erythematosus. BMC Med., 2013, 11(1), 120.
50. Yeo, S.C.; Liew, A.; Barratt, J. Emerging therapies in IgA nephropathy. Nephrology (Carlton), 2015, 20(11), 788-800
51. Lilly, E. FDA approves Trulicity (dulaglutide), Lilly’s once-weekly therapy for adults with type 2 diabetes. Press release, September 18, 2014. [Available at: https://investor.lilly.com/releasedetail.cfm?releaseid=871658].
52. Drucker, D.J.; Nauck, M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet, 2006, 368(9548), 1696-1705.
53. Campbell, R.K. Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus. Ann. Pharmacother., 2007, 41(1), 51-60.
54. Meier, J.J. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol., 2012, 8(12), 728-742.
55. Sebokova, E.; Christ, A.D.; Wang, H.; Sewing, S.; Dong, J.Z.; Taylor, J.; Cawthorne, M.A.; Culler, M.D. Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. Endocrinology, 2010, 151(6), 2474-2482.
56. Dungan, K.M.; Povedano, S.T.; Forst, T.; González, J.G.; Atisso, C.; Sealls, W.; Fahrbach, J.L. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet, 2014, 384(9951), 1349-1357.
57. Umpierrez, G.; Tofé Povedano, S.; Pérez Manghi, F.; Shurzinske, L.; Pechtner, V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care, 2014, 37(8), 2168-2176.
58. Kunz, C.; Fey, S.; Obländer, J.; Brendel, S.; Klaumünzer, M.; Mossner, M. The new CD95 ligand inhibitor APG101 leads to decreased apoptosis and improved erythroid differentiation in primary CD34+ cells from patients with low risk myelodysplastic syndrome (MDS). Blood, 2013, 122(21), 1562.
59. Barnhart, B.C.; Legembre, P.; Pietras, E.; Bubici, C.; Fran-zoso, G.; Peter, M.E. CD95 ligand induces motility and in-vasiveness of apoptosis-resistant tumor cells. EMBO J., 2004, 23(15), 3175-3185.
60. Adamson, C.; Kanu, O.O.; Mehta, A.I.; Di, C.; Lin, N.; Mattox, A.K. Glioblastoma multiforme: A review of where we have been and where we are going. Expert. Opin. Investig. Drugs, 2009, 18(8), 1061-1083.
61. Tuettenberg, J.; Seiz, M.; Debatin, K-M.; Hollburg, W.; von Staden, M.; Thiemann, M.; Hareng, B.; Fricke, H.; Kunz, C. Pharmacokinetics, pharmacodynamics, safety and tolerability of APG101, a CD95-Fc fusion protein, in healthy volunteers and two glioma patients. Int. Immunopharmacol., 2012, 13(1), 93-100.
62. Weller, M.; Cloughesy, T.; Perry, J.R.; Wick, W. Standards of care for treatment of recurrent glioblastomaare we there yet? Neuro. Oncol., 2013, 15(1), 4-27.
63. Cheson, B.D.; Bennett, J.M.; Kantarjian, H.; Pinto, A.; Schiffer, C.A.; Nimer, S.D.; Löwenberg, B.; Beran, M.; de Witte, T.M.; Stone, R.M.; Mittelman, M.; Sanz, G.F.; Wi-jermans, P.W.; Gore, S.; Greenberg, P.L. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood, 2000, 96(12), 3671-3674.
64. DiGiulio, S. FDA Grants Apocept (APG101) Orphan Drug Status for MDS; Oncology Times, 2013.
65. Fricke, H.; Fontenay, M. Inhibitors Of The Cd95 Signaling Pathway For Treatment Of Mds. U.S. Patent 20,150,166,632; 2015.
66. Luft, T.; Fey, S.; Obländer, J.; Brendel, S.; Pressler, J.; Jann, J.C. The fas ligand inhibitor APG101 in transfusion dependent patients with low risk MDS: interim results from a phase I study. Blood, 2014, 124(21), 4669.
67. Pérez-Ruixo, J.J.; Krzyzanski, W.; Bouman-Thio, E.; Miller, B.; Jang, H.; Bai, S.A.; Zhou, H.; Yohrling, J.; Cohen, A.; Burggraaf, J.; Franson, K.; Davis, H.M. Pharmacokinetics and pharmacodynamics of the erythropoietin Mimetibody construct CNTO 528 in healthy subjects. Clin. Pharmacokinet., 2009, 48(9), 601-613.
68. Bugelski, P.; Nesspor, T.; Spinka-Doms, T.; Makropoulos, D.; Eirikis, E.; Fisher, J.; Volk, A.; Shamberger, K.; James, I.; Fisher, P.; Pool, C;.; Jang, H.; Miller, B.; Huang, C.; Heavner, G.; Knight, D.; Ghrayeb, J.; Scallon, B. Pharmacokinetics and pharmacodynamics of CNTO 528, a novel erythropoietin receptor agonist in normal and anemic rats. Blood, 2005, 106, 4261.
69. Bouman-Thio, E.; Franson, K.; Miller, B.; Getsy, J.; Cohen, A.; Bai, S.A.; Yohrling, J.; Frederick, B.; Marciniak, S.; Jiao, Q.; Jang, H.; Davis, H.; Burggraaf, J. A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immu-nogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects. J. Clin. Pharmacol., 2008, 48(10), 1197-207.
70. Bugelski, P.J.; Capocasale, R.J.; Makropoulos, D.; Marshall, D.; Fisher, P.W.; Lu, J.; Achuthanandam, R.; Spinka-Doms, T.; Kwok, D.; Graden, D.; Volk, A.; Nesspor, T.; James, I.E.; Huang, C. CNTO 530: molecular pharmacology in human UT-7EPO cells and pharmacokinetics and pharmacodynamics in mice. J. Biotechnol., 2008, 134(1-2), 171-180.
71. Martin, P.L.; Sachs, C.; Hoberman, A.; Jiao, Q.; Bugelski, P.J. Effects of CNTO 530, an erythropoietin mimetic-IgG4 fusion protein, on embryofetal development in rats and rabbits. Birth Defects Res. B Dev. Reprod. Toxicol., 2010, 89(2), 87-96.
72. Makropoulos, D.A.; Achuthanandam, R.; Avery, J.; Wilson, K.; Brosnan, K.; Miller, A.; Nesspor, T.; Chroscinski, D.; Walker, M.; Egenolf, D.; Huang, C.; Bugelski, P.J. CNTO 530 increases expression of HbA and HbF in murine models of ß-thalassemia and sickle cell anemia. Curr. Pharm. Biotechnol., 2013, 14(2), 242-248.
73. Dranoff, G.; Vanneman, M.; Freeman, G. Nkg2d-fc for immunotherapy; Google Patents, US20110311535, 2011.
74. Raab, S.; Steinbacher, J.; Schmiedel, B.J.; Kousis, P.C.; Steinle, A.; Jung, G.; Grosse-Hovest, L.; Salih, H.R. Fc-optimized NKG2D-Fc constructs induce NK cell antibody-dependent cellular cytotoxicity against breast cancer cells independently of HER2/neu expression status. J. Immunol., 2014, 193(8), 4261-4272.
75. Steinbacher, J.; Baltz-Ghahremanpour, K.; Schmiedel, B.J.; Steinle, A.; Jung, G.; Kübler, A.; André, M.C.; Grosse-Hovest, L.; Salih, H.R. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia. Int. J. Cancer, 2015, 136(5), 1073-1084.
76. Zhu, X.; Marcus, W.D.; Xu, W.; Lee, H.I.; Han, K.; Egan, J.O.; Yovandich, J.L.; Rhode, P.R.; Wong, H.C. Novel human interleukin-15 agonists. J. Immunol., 2009, 183(6), 3598-3607.
77. Gomes-Giacoia, E.; Miyake, M.; Goodison, S.; Sriharan, A.; Zhang, G.; You, L.; Egan, J.O.; Rhode, P.R.; Parker, A.S.; Chai, K.X.; Wong, H.C.; Rosser, C.J. Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One, 2014, 9(6), e96705.
78. Mathios, D.; Park, C.K.; Marcus, W.D.; Alter, S.; Rhode, P.R.; Jeng, E.K.; Wong, H.C.; Pardoll, D.M.; Lim, M. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model. Int. J. Cancer, 2016, 138(1), 187-194.
79. Xu, W.; Jones, M.; Liu, B.; Zhu, X.; Johnson, C.B.; Edwards, A.C.; Kong, L.; Jeng, E.K.; Han, K.; Marcus, W.D.; Rubinstein, M.P.; Rhode, P.R.; Wong, H.C. Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor aSu/Fc fusion complex in syn-geneic murine models of multiple myeloma. Cancer Res., 2013, 73(10), 3075-3086.
80. Jones, R.B.; Mueller, S.; OConnor, R.; Rimpel, K.; Sloan, D.D.; Karel, D.; Wong, H.C.; Jeng, E.K.; Thomas, A.S.; Whitney, J.B.; Lim, S.Y.; Kovacs, C.; Benko, E.; Karan-dish, S.; Huang, S.H.; Buzon, M.J.; Lichterfeld, M.; Irrinki, A.; Murry, J.P.; Tsai, A.; Yu, H.; Geleziunas, R.; Trocha, A.; Ostrowski, M.A.; Irvine, D.J.; Walker, B.D. A subset of latency-reversing agents expose HIV-infected resting CD4+ T-cells to recognition by cytotoxic T-lymphocytes. PLoS Pathog., 2016, 12(4), e1005545.
81. Seay, K.; Church, C.; Zheng, J.H.; Deneroff, K.; Ochsen-bauer, C.; Kappes, J.C.; Liu, B.; Jeng, E.K.; Wong, H.C.; Goldstein, H. In vivo activation of human NK cells by treatment with an interleukin-15 superagonist potently inhibits acute in vivo HIV-1 infection in humanized mice. J. Virol., 2015, 89(12), 6264-6274.
82. Lebwohl, M.; Christophers, E.; Langley, R.; Ortonne, J.P.; Roberts, J.; Griffiths, C.E. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch. Dermatol., 2003, 139(6), 719-727.
83. Hoffman, H.M.; Throne, M.L.; Amar, N.J.; Sebai, M.; Kiv-itz, A.J.; Kavanaugh, A.; Weinstein, S.P.; Belomestnov, P.; Yancopoulos, G.D.; Stahl, N.; Mellis, S.J. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebo-controlled studies. Arthritis Rheum., 2008, 58(8), 2443-2452.
84. Kuter, D.J.; Bussel, J.B.; Lyons, R.M.; Pullarkat, V.; Gern-sheimer, T.B.; Senecal, F.M.; Aledort, L.M.; George, J.N.; Kessler, C.M.; Sanz, M.A.; Liebman, H.A.; Slovick, F.T.; de Wolf, J.T.; Bourgeois, E.; Guthrie, T.H., Jr; Newland, A.; Wasser, J.S.; Hamburg, S.I.; Grande, C.; Lefrère, F.; Li-chtin, A.E.; Tarantino, M.D.; Terebelo, H.R.; Viallard, J.F.; Cuevas, F.J.; Go, R.S.; Henry, D.H.; Redner, R.L.; Rice, L.; Schipperus, M.R.; Guo, D.M.; Nichol, J.L. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet, 2008, 371(9610), 395-403.
85. Heier, J.S.; Brown, D.M.; Chong, V.; Korobelnik, J-F.; Kaiser, P.K.; Nguyen, Q.D.; Kirchhof, B.; Ho, A.; Ogura, Y.; Yancopoulos, G.D.; Stahl, N.; Vitti, R.; Berliner, A.J.; Soo, Y.; Anderesi, M.; Groetzbach, G.; Sommerauer, B.; Sandbrink, R.; Simader, C.; Schmidt-Erfurth, U. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology, 2012, 119(12), 2537-2548.
86. Wang, T-F.; Lockhart, A.C. Aflibercept in the treatment of metastatic colorectal cancer. Clin. Med. Insights Oncol., 2012, 6, 19-30.
87. Peyvandi, F.; Rosendaal, F.R.; OMahony, B.; Mannuccio, M.P. Pediatric requirements in Europe stymie help for hemophilia. Nat. Med., 2014, 20(2), 117.
88. The U.S. Food and Drug Administration. Department of Health and Human Services. FDA NEWS RELEASE. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm391037.htm [Accessed March 9, 2017].
89. Kim, P.S.; Kwilas, A.R.; Xu, W.; Alter, S.; Jeng, E.K.; Wong, H.C.; Schlom, J.; Hodge, J.W. IL-15 superagonist/IL-15RaSushi-Fc fusion complex (IL-15SA/IL-15RaSu-Fc; ALT-803) markedly enhances specific sub-populations of NK and memory CD8+ T cells, and mediates potent anti-tumor activity against murine breast and colon carcinomas. Oncotarget, 2016, 7(13), 16130-16145.